TORONTO AND CAMBRIDGE, MA, January 6, 2022. Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 10 ...

Former Moderna CMO and COVID-19 vaccine lead brings experience building hugely successful mRNA therapeutics company to Deep Genomics. 

TORONTO AND CAMBRIDGE, MA, October 26, 2021. Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, M.D., Ph.D., to its Strategic Advisory Board, effective ...

MONTREAL and TORONTO – September 20, 2021 – Mila, the Quebec Artificial Intelligence Institute, today announced the start of a partnership with Deep Genomics, a leading company in therapeutic artificial intelligence treatments. This collaboration will allow the company to join Mila's community and to take advantage ...

-       Company expands AI discovery platform for ‘Programmable’ RNA therapeutics and supports advancement of its portfolio into the clinic 

-       Oversubscribed round led by SoftBank Vision Fund 2, with CPP Investments, Fidelity Management & Research Company LLC, Alexandria Venture Investments, Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and ...

TORONTO – May 3, 2021. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, Preclinical Research. Jeffrey will be responsible for advancing programs into IND-enabling studies, overseeing the discipline of experimental biology, and working with ...

SAN RAFAEL and TORONTO, Nov. 17, 2020 — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in ...